Rituximab as maintenance therapy for patients with follicular lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab as maintenance therapy for patients with follicular lymphoma

Published:2009-04-15 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Vidal Liat¹,Gafter-Gvili Anat²,Leibovici Leonard²,Shpilberg Ofer³

Affiliation:

1. Beilinson Campus, Rabin Medical Center; Department of Internal Medicine E; 39 Jabotinsky Street Petah-Tiqva Israel 49100

2. Beilinson Campus, Rabin Medical Center; Department of Medicine E; 39 Jabotinsky Street Petah-Tiqva Israel 49100

3. Rabin Medical Center; Institute of Hematology; Petah-Tikva Israel 49100

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006552.pub2/fullpdf

Reference58 articles.

1. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG);Forstpointner;Blood,2006

2. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK);Ghielmini;Annals of Oncology,2005

3. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule;Ghielmini;Blood,2004

4. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network;Hainsworth;Journal of Clinical Oncology,2005

5. Hochster HS Weller E Gascoyne RD Ryan TS Habermann TM Gordon LI Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B Blood (ASH Annual Meeting Abstracts) 2005 Abstract 349

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review;Pharmaceuticals;2024-02-21

2. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab;Annals of Allergy, Asthma & Immunology;2023-06

3. Infectious Complications in Autoimmune Hemolytic Anemia;Journal of Clinical Medicine;2021-01-05

4. Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis;Journal of Chemotherapy;2015-04-15

5. Anthracycline-containing regimens for treatment of follicular lymphoma in adults;Cochrane Database of Systematic Reviews;2013-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3